Safety of alitretinoin for severe refractory chronic hand eczema: Clinical studies and postmarketing surveillance

Abstract

Background: Alitretinoin is approved for the treatment of adults with severe chronic hand eczema (CHE) refractory to potent topical steroids. In the 6 years since launch, approximately 250 000 patients have been treated with alitretinoin. Objective: To compare the postmarketing safety surveillance experience of alitretinoin with data from clinical trials and key safety issues with other retinoids. Methods: An integrated safety analysis of the pivotal studies of alitretinoin and postmarketing adverse event (AE) reports received since approval for alitretinoin were analyzed. Results: In the pivotal trials, headache, erythema, nausea, increased blood triglycerides and increased blood creatinine phosphokinase were the most frequently reported AEs. Headache, hyperlipidemia and nausea were also frequently reported postmarketing AEs, but depression was relatively more frequently reported than in the pivotal trials. Inflammatory bowel disease and benign intracranial hypertension were rare, and very few cases have been reported in postmarketing surveillance. There have been no reports of teratogenicity in humans consequent to fetal exposure. Conclusions: Safety data collected in pivotal trials and postmarketing surveillance suggest that alitretinoin is well tolerated by patients with CHE with a relatively low incidence of serious reactions. The adverse reaction profile is congruent with reported effects of other marketed oral retinoids.

• Adverse reactions
• drug surveillance
• dermatitis
• retinoid
• toxicity, Toctino

Acknowledgements

Assistance with the preparation of this manuscript was provided by Daniel Sinsimer, PhD and Skye Geherin, PhD (production of draft outline and first draft, and collation of authors’ comments), and Sue Landry (copyediting) at MediTech Media and was funded by Stiefel – a GSK company.

Declaration of interest

The authors are employed by GlaxoSmithKline companies and own vested stock.

This study was funded by GSK.